June Election: FDA Reproductive Health Drugs Panel Holds On To Hager For Second Term

This article was originally published in The Pink Sheet Daily

07 Jul 2004
News

The Pink Sheet Daily pinkeditor@informa.com

Executive Summary

Plan B OTC opponent Hager reappointed to FDA’s Reproductive Health Drugs Advisory Committee, effective June 30. Hager’s term was renewed for another year after an unusually short previous appointment expired and despite an effort by several House members to block his reappointment.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS060213

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS060213

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

June Election: FDA Reproductive Health Drugs Panel Holds On To Hager For Second Term

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert